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Abstract Fenofibrate and fasting are known to regulate several
genes involved in lipid metabolism in a similar way. In this study
measuring several mitochondrial enzyme activities, we demon-
strate that, in contrast to citrate synthase and complex II,
cytochrome c oxidase (COX) is a specific target of these two
treatments. In mouse liver organelles, Western blot experiments
indicated that mitochondrial levels of p43, a mitochondrial T3
receptor, and mitochondrial peroxisome proliferator activated
receptor (mt-PPAR), previously described as a dimeric partner
of p43 in the organelle, are increased by both fenofibrate and
fasting. In addition, in PPARK-deficient mice, this influence was
abolished for mt-PPAR but not for p43, whereas the increase in
COX activity was not altered. These data indicate that: (1)
PPARK is involved in specific regulation of mt-PPAR expression
by both treatments; (2) fenofibrate and fasting regulate the
mitochondrial levels of p43 and thus affect the efficiency of the
direct T3 mitochondrial pathway. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
L-Oxidation is a major process by which fatty acids are
oxidized. From this reaction, mitochondria produce most of
the energy in animal cells through the oxidative phosphoryla-
tion chain containing enzymatic subunits encoded by both
nuclear and mitochondrial genes.
Several peroxisome proliferators (PPs) such as ¢brate [1]
have been shown to activate peroxisome proliferator activated
receptors (PPARs) which are members of the steroid nuclear
receptor superfamily [1,2]. PPs are known to activate enzymes
involved in the regulation of lipid metabolism (peroxisomal
and mitochondrial L-oxidation, microsomal g-hydroxylation
and ketone body synthesis) [2^7]. Several studies have also
underlined that fasting, like PP exposure, induces L-oxidation
gene expression, probably by increasing fatty acid levels [8,9].
Moreover, experiments performed in PPARK-de¢cient mice
(PPARK3/3) established that this nuclear receptor is needed
for the induction by ¢brate or fasting of several genes in-
volved in lipid oxidation such as acyl-CoA oxidase, enoyl-
CoA hydratase and 3-ketoacyl-CoA thiolase [8^11]. These ob-
servations point to a key role for PPARK in lipid homeostasis.
Like thyroid hormone [12^17], PPs regulate mitochondrial
activity [18^20]. They alter mitochondrial morphology and
enzyme composition [21^23]. In addition, they also increase
mitochondrial mRNA and rRNA levels [18]. Today, it has
been proposed that PPs, such as feno¢brate, indirectly act
at organelle level through the PPAR nuclear pathway.
In addition to the well-known mitochondrial transcription
factor mt-TFA [24], we have previously demonstrated that a
triiodothyronine receptor (p43) located in the mitochondrial
matrix is a potent mitochondrial transcription factor [16,17].
Moreover, we have characterized a 45 kDa protein immuno-
logically related to PPARQ2 (naming it mt-PPAR), occurring
in the mitochondrial matrix [25]. Interestingly, mt-PPAR and
p43 have been detected in a common complex which binds to
a DR2 sequence of the mitochondrial D-loop [25].
In the present work, we have studied the in£uence of feno-
¢brate treatment or fasting on p43 and mt-PPAR mitochon-
drial levels in relation to mitochondrial activity. We also
tested the possible involvement of the nuclear receptor PPARK
in the regulation of these factors by using liver mitochondria
extracted from control or PPARK-de¢cient mice. We report
here that feno¢brate or fasting do not in£uence mt-TFA
amounts but increase mitochondrial levels of p43 and mt-
PPAR in a similar way. In addition, we found that PPARK
is involved in the regulation of mt-PPAR expression.
2. Materials and methods
2.1. Animals
Feno¢brate treatment or fasting were carried out in control
(C57BL/6) or PPARK-de¢cient mice on a C57BL/6 background
[10,11]. In the ¢rst experiment, all animals were allowed free access
to food. They were assigned to four groups: a control group (n = 6)
receiving a single intraperitoneal injection of the vehicle used for fe-
no¢brate administration; a treated group (n = 6) receiving a single
intraperitoneal injection of feno¢brate (300 mg/kg); two groups
were constituted in the PPARK3/3 mice (n = 6 in each group). As
with the control mice, the ¢rst group received only the vehicle, where-
as the second received the feno¢brate treatment previously described.
In a second experiment, using a similar procedure, six control and six
PPARK3/3 mice were allowed free access to food and were killed 3 h
following the beginning of the dark, and the remaining two groups
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were starved for 30 h. At this stage, all animals were killed between
9 and 11 a.m. and the livers were collected and immediately frozen in
liquid nitrogen.
2.2. Mitochondria preparations and enzymatic activities
Liver mitochondria were prepared by di¡erential centrifugation ac-
cording to Wrutniak et al. [16]. Citrate synthase, cytochrome c oxi-
dase (COX) and succinate ubiquinone oxidoreductase (complex II)
activities were measured according to Rochard et al. [26].
2.3. Western blot analysis
Mitochondrial proteins (50 Wg) were electrophoresed through SDS^
PAGE gel, transferred to a PDVF membrane and detected by a
chemiluminescent Western blot procedure. Anti-RHTII, anti-PPARQ2
and anti-mt-TFA antisera have been described previously [16,17,25].
Anti-E2-PDH antiserum was kindly provided by Dr C. Marsac (IN-
SERM, Paris). Quanti¢cation of signal intensities was carried out with
a PhosphorImager (Molecular Dynamics) and normalized against E2-
PDH used as invariant.
3. Results
3.1. Feno¢brate treatment or fasting speci¢cally increased
COX activity
To test the in£uence of feno¢brate or fasting upon mito-
chondrial activity, we measured several enzymatic activities:
two enzymes encoded by nuclear genes, citrate synthase (a key
enzyme of the tricarboxylic acid cycle) and succinate ubiqui-
none oxidoreductase (complex II), and one enzymatic com-
plex encoded by both nuclear and mitochondrial genes, COX.
In control or PPARK3/3 mice, feno¢brate did not in£u-
ence citrate synthase and complex II activities (Table 1). On
the other hand, it induced a signi¢cant rise in COX activity in
control animals as well as in mice lacking PPARK (Table 1).
Similar changes in COX activities were induced by fasting in
control or PPARK-de¢cient mice (Table 1). In addition, as
described for feno¢brate, fasting did not in£uence citrate syn-
thase or complex II activities (Table 1).
3.2. Feno¢brate treatment or fasting increased p43 and
mt-PPAR mitochondrial levels
The observation that, in contrast to citrate synthase or
complex II, COX activity is up-regulated by feno¢brate or
fasting suggests a major in£uence of these treatments on mi-
tochondrial genome expression. To test this possibility, we
studied their in£uence on the mitochondrial amounts of mt-
TFA, a constitutive transcription factor of the organelle, and
p43, a T3-dependent mitochondrial transcription factor. The
amounts of the mitochondrial PPARQ2-related protein, mt-
PPAR [25], were also monitored.
In comparison to control mice, feno¢brate induced an up to
two-fold increase in the levels of p43 or mt-PPAR (Fig. 1). In
addition, whereas the induction of mt-PPAR by feno¢brate
was completely abolished in mice lacking PPARK, the rise in
amounts of p43 was not altered in these animals (Fig. 1).
Similar results were obtained for the in£uence of fasting
(Fig. 2). However, the mitochondrial levels of mt-TFA were
not altered by feno¢brate, fasting or in PPARK gene invalid-
ation (Fig. 3).
4. Discussion
In the present study, we found that feno¢brate or fasting do
not in£uence citrate synthase or complex II activity. On the
other hand, these treatments induced a signi¢cant rise in COX
activity. Such a di¡erence could re£ect the genetic origin of
these enzymes. Whereas the latter are encoded by nuclear
genes, COX is a multimeric complex involving distinct sub-
units encoded by nuclear genes and by the mitochondrial ge-
nome. Therefore, speci¢c regulation of COX activity by feno-
¢brate or fasting suggests that the two treatments a¡ect
Fig. 1. Feno¢brate treatment increased the mitochondrial levels of
p43 and mt-PPAR. Data are derived from Western blot analysis of
mitochondrial proteins (50 Wg) using rat liver mitochondrial extracts
and anti-RHTII, anti-PPARQ2 or anti-E2-PDH antisera. Quanti¢ca-
tion of signal intensities was carried out with a PhosphorImager
(Molecular Dynamics) and normalized against the levels of the mi-
tochondrial protein E2-PDH. Data are expressed as the mean of re-
sults obtained in four animals. *P6 0.01; **P6 0.05 relative to
control.
Fig. 2. Fasting increased the mitochondrial levels of p43 and mt-
PPAR. Data are derived from Western blot analysis of mitochon-
drial proteins (50 Wg) using rat liver mitochondrial extracts and
anti-RHTII, anti-PPARQ2 or anti-E2-PDH antisera. Quanti¢cation
of signal intensities was carried out with a PhosphorImager (Molec-
ular Dynamics) and normalized against the levels of the mitochon-
drial protein E2-PDH. Data are expressed as the mean of results
obtained in four animals. *P6 0.01 relative to control.
Fig. 3. Mitochondrial levels of mt-TFA are not altered by feno¢-
brate or fasting. Data are derived from Western blot analysis of mi-
tochondrial proteins (50 Wg) using rat liver mitochondrial extracts
and anti-mt-TFA antiserum. Mt-TFA synthesized in rabbit reticulo-
cyte was used as control. Quanti¢cation of signal intensities was
carried out with a PhosphorImager (Molecular Dynamics) and nor-
malized against the levels of the mitochondrial proteins E2-PDH.
Data are expressed as the mean of results obtained in four animals.
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mitochondrial activity essentially by stimulating mitochon-
drial genome transcription, as already described [18].
In previous studies, we demonstrated the occurrence of
truncated forms of members of the nuclear receptor family
in the mitochondrial matrix [16,25]. We have also established
that p43, a T3-binding protein synthesized by the use of an
internal AUG occurring in the c-erb AK1 mRNA [27] acts as
a T3-dependent transcription factor of the mitochondrial ge-
nome [17]. In addition, we demonstrated [25] that it binds to
the mitochondrial D-loop by forming a complex including mt-
PPAR, a PPARQ2-related protein devoid of the carboxy-ter-
minus of the nuclear receptor.
Interestingly, we report here that stimulation of organite
activity by feno¢brate or fasting is related to an increase in
mitochondrial amounts of p43. As we have shown that p43
overexpression stimulates mitochondrial genome transcription
[17] and COX activity [16], but not citrate synthase activity,
we suggest that such a mechanism is involved in the in£uence
of the two treatments at mitochondrial level. This possibility
is concordant with the present observation that regulation of
p43 expression is not abolished in PPARK-de¢cient mice, and
that stimulation of COX activity is not grossly impaired in
these animals. In addition, the observation that mt-TFA is
not in£uenced by feno¢brate or fasting suggests that this con-
stitutive mitochondrial transcription factor is not involved in
the regulation of mitochondrial activity.
Another striking result is the observation that, as previously
reported for PPARQ nuclear receptors [28], mt-PPAR
amounts are increased by a feno¢brate treatment. This is con-
cordant with the stimulation of mt-PPAR abundance by clo-
¢brate in rat liver mitochondria already documented [25]. In
contrast to p43, this regulation is abrogated in PPARK-de¢-
cient mice, thus suggesting that this nuclear receptor plays a
key role in the regulation of mt-PPAR expression. However,
despite the lack of in£uence of ¢brate or fasting on mt-PPAR
in PPARK-de¢cient mice, stimulation of COX activity is
maintained in knocked-out animals in these conditions.
Our data indicate that the rise in COX activity and mito-
chondrial amounts of p43 induced by feno¢brate also oc-
curred in PPARK3/3 mice. This is probably an interesting
result clearly establishing that not all ¢brate in£uences are
mediated by the nuclear receptor PPARK.
In conclusion, this study clearly suggests that ¢brates and
fasting in£uence mitochondrial activity, and that this action
occurs essentially at the level of the mitochondrial genome.
Moreover, their in£uence on the amounts of mitochondrial
regulators, such as p43 and mt-PPAR, is probably involved
in this regulation. In addition to a recent paper demonstrating
that there is a low reserve of COX activity in vivo [29], this
observation suggests that the in vivo control of respiration by
COX activity could be dependent on mitochondrial genome
encoded subunits.
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